PTHS · Pelthos Therapeutics
AI read · Good for PTHS
The AI's read
Pelthos reported Q2 revenue jumped to $15.4M from $10.7M, driven by a 48% rise in Zelsuvmi prescriptions and a PBM deal that widens distribution. The company also flagged two complementary products slated for 2027 that add commercial optionality. The market reaction is muted and slightly negative, with the stock down 2.2% and RSI ~44, so the beat isn't being rewarded today. Shares haven't run yet and valuation isn't stretched, so the report looks at least partly unpriced. We lean bullish because growth is tangible, the PBM agreement reduces a distribution hurdle, and new-product optionality can re-rate the name. But the current consolidation regime and elevated whipsaw risk mean we'd size small and keep tight risk control.